Gelteq Limited
Gelteq Limited is a biotechnology company focused on developing and commercializing gel-based delivery solutions for human and animal health. Gelteq Limited’s proprietary Gelteq® platform is designed to improve how active ingredients are formulated, stabilized, and absorbed, supporting more precise dosing and better bioavailability. The company works with partners across pharmaceutical, consumer health, nutraceutical, sports nutrition, over-the-counter, and pet care markets, offering research and development, product creation, and manufacturing services. Its portfolio includes edible gel formulations that can be white-labeled and adapted for prescription drugs and other ingestible products. Based in Melbourne, Australia, Gelteq Limited plays a specialized role in oral delivery innovation, helping translate active ingredients into gel formats intended for easier consumption and broader product applications.
$0.45
+$0.02 (+3.48%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-2988.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -10.27% to -20.07%, capital efficiency is deteriorating. Negative free cash flow of -A$6M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
A$166K
Net Income (TTM)
-A$7M
▼ -87.4% YoY
Op. Margin
-2988.98%
ROIC
-20.07%
▼ -9.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-A$6M
▼ -405.8% YoY
Op. Cash Flow (TTM)
-A$6M
▼ -405.8% YoY
Net Debt
A$4M
Cash & Equiv.
A$345K
3Y CAGR: +3.9%
Continue Research
Is Gelteq (GELS) overvalued?
Gelteq (GELS)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Gelteq scores 16/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Gelteq a high-quality business?+
Gelteq scores 16 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -2,989.0% operating margin and a -20.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Gelteq a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh GELS's valuation and scores 16/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.